South Florida Radiation Oncology Treats First Cancer Patients Using Its New CyberKnife® M6™ System
South Florida Radiation Oncology is part of
"I've used the CyberKnife System for more than 10 years. It is my 'go to' radiation therapy device for treating tumors near critical organs where extraordinary precision and accuracy are required," said Dr. Perman. "Using the CyberKnife M6 with the InCise MLC, lung and prostate SBRT treatments can now be delivered in standard radiation therapy treatment times. Our ability to deliver the highest levels of precision and shorter treatment times for more patients each day is nothing short of amazing."
The CyberKnife System has evolved to reflect advances in stereotactic radiation therapy, transforming the treatment of both malignant and benign tumors within all areas of the body. The system's ability to automatically stay on target despite patient and tumor motion is what differentiates it from other types of radiation therapy delivery systems. It tracks the tumor continually throughout the treatment session so that it can deliver radiation to where the tumor is, not where it used to be. This unique dynamic tracking and correction capability – the only one of its kind – enables physicians to deliver high doses of radiation with exceptional accuracy while minimizing side effects. The result is personalized treatment designed to meet the unique needs of each patient.
"We're proud to support Dr. Perman, Dr. Crook and their team in their efforts to improve the lives of people diagnosed with cancer. Their real-world experiences using the CyberKnife M6 System with the InCise MLC demonstrates greater versatility and efficiency for delivering radiation therapy treatments," said Lionel Hadjadjeba, M.D., Senior Vice President, and Chief Commercial Officer at
Important Safety Information
For Important Safety Information please refer to http://www.accuray.com/safety-statement.
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to clinical applications, clinical results, and
Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.
+1 (408) 789-4426
+1 (781) 684-6662
View original content with multimedia:http://www.prnewswire.com/news-releases/south-florida-radiation-oncology-treats-first-cancer-patients-using-its-new-cyberknife-m6-system-300634598.html